Evidence that hematopoietic stem cells in human umbilical cord blood is infectable by dengue virus: proposing a vertical transmission candidate

Amrita Vats a, Tzu-Chuan Ho a, Irwin Puc b, Yi-Ju Chen b, Chiung-Hsin Chang c, Yu-Wen Chien d,e, Guey-Chuen Pernga,b,*

a Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
b Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
c Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
d Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan
e Department of Occupational and Environmental Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

ARTICLE INFO
Keywords:
- Dengue virus
- Umbilical cord blood
- CD133+
- CD34+
- Hematopoietic stem cells

ABSTRACT
Background: Recent studies have shown that dengue virus (DENV) can efficiently infect bone marrow hematopoietic stem cells (HSCs) as well as the placenta of pregnant women. Although mother-to-infant vertical transmission of DENV through the placenta has been well documented, the evidence of cell-associated vertical transmission is still unknown. Whether DENV can infect umbilical cord blood (UCB) cells before reaching the fetus remains to be explored. Here, we proposed that human UCB cells were permissive to the DENV infection and DENV infected CD133+ and CD34+ HSCs are reservoir of the virus that could be reactivated upon re-culturing in suitable cells.

Methods: Human UCB cells were freshly obtained and subjected to DENV infection. Multicolor flow cytometry (MFCM) was used to demonstrate the phenotypes of the infected HSC populations. Immunofluorescence analysis (IFA) and T-distributed Stochastic Neighbor Embedding (t-SNE) were used to show the association of the DENV antigen, non-structural protein1 (NS1) with HSCs.

Key findings: UCB cells were highly permissive to DENV infection. DENV altered the phenotype of the infected HSC population, increased the expression of HSCs, and affected the balance of transcription factors (TFs, GATA1/2/3). IFA revealed the association of the DENV antigen, non-structural protein1 (NS1) with HSCs. T-distributed Stochastic Neighbor Embedding (t-SNE) analysis revealed heterogeneity in the distribution of CD133+NS1+ and CD34+NS1+ cells. DENV particles were recovered from CD133+ and CD34+ cells even when virus production in the supernatant was negligible.

Significance: We predict that infection of CD133+ and CD34+ cells in the UCB serve as reservoirs for the amplification of DENV in UCB prior to the virus reaching the fetus and facilitate vertical transmission.

1. Introduction
Dengue is a serious global public health problem in both tropical and sub-tropical areas. According to the World Health Organization (WHO), 3.9 billion people in 128 countries are currently at risk of dengue infection, and most cases are asymptomatic [1, 2]. The dengue virus (DENV), an arbovirus of the family Flaviviridae, is frequently transmitted to humans by Aedes spp. Mosquitoes [3, 4]. Cases of dengue have also been documented to be infected through unconventional routes, such as blood transfusion, bone marrow, stem cells, and organ transplantations [5, 6]. However, vertical transmission of DENV from mother to fetus has received relatively little attention [7, 8, 9]. In one prospective study, 5.8% of newborns showed warning signs of congenital infection and vertical transmission rates were estimated to be as high as 18.5% [10]. In a Brazilian case study, approximately 30% of pregnant women with symptomatic dengue had at least one clinical or biological warning sign, and they were 3.4 times more likely to develop severe dengue [11]. Moreover, maternal dengue carries the risk of adverse fetal outcomes, such as miscarriage, stillbirth, preterm birth, and low birth weight and subclinical or inapparent infection in young children [12, 13]. One to five

* Corresponding author.
E-mail address: gperng@mail.ncku.edu.tw (G.-C. Perng).

https://doi.org/10.1016/j.heliyon.2021.e06785
Received 21 August 2020; Received in revised form 8 December 2020; Accepted 8 April 2021
2405-8440/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
percent of infants hospitalized due to severe dengue have dengue-immune mothers [14, 15].

DENV neutralizing antibody is commonly present in mothers of infants with primary dengue in endemic countries [16, 17]. Seropositivity rate was found to be 35.8% in Malaysia and as high as 94.7% in Thailand [18, 19]. Maternally derived, neutralizing anti-DENV antibodies are postulated to confer immunity to dengue during the first months of life [20]. The prime cause of fetal and neonatal morbidity and mortality in DENV infection during pregnancy is insufficient maternally derived IgG neutralizing antibodies. The incremental decay of the IgG antibody generates a window period that possesses sub-neutralizing levels of antibody, which effectively enhances DENV infection in Fc receptor-bearing host cells and uncontrollable viremia, implying the corollary of antibody-dependent enhancement of DENV infectivity [19, 20]. However, it is still mysterious whether sub-neutralizing levels of maternally derived anti-DENV IgG increases fetal DENV infection risk. Ample evidence suggests that increasing IgG catabolism, due to high competition and mutation among IgGs, causes loss of binding and interaction to FcRn receptors, which reduces the transfer of maternal IgG antibodies to neonates [21, 22]. The ambiguous nature of maternally derived neutralizing antibody makes it much more difficult to define its roles in DENV transmission to the fetus.

A growing body of evidence indicates that bone marrow hematopoietic stem and progenitor cells are permissive to DENV infection and can efficiently infect hematopoietic stem cells, leading marrow suppression [23, 24, 25, 26]. Vertical transmission of DENV poses a risk of fetal death, because of thrombocytopenia in the newborn that entails platelet transfusion [27, 28]. The complex process of platelet production starts with hematopoietic stem cell (HSC) differentiation and megakaryocyte (MK) lineage commitment, which is followed by MK maturation and platelet release [29, 30]. Congenital DENV infection usually occurs during late pregnancy and is caused by direct transfer of the virus across the maternal placenta through the umbilical cord blood (UCB), thus resulting in neonatal infection [31, 32]. Cord blood leucocytes have been shown to support DENV2 replication in vitro [33]. DENV has been discovered in the placenta, UCB, and serum of fetuses in pregnant women [34, 35]. UCB, a critical bridge and carrier that transfers nourishment from the mother to the fetus, has been found to contain maternal cell contaminants with a substantial amount of hematopoietic stem and progenitor cells, including CD34 cells [36, 37]. Additionally, these cells may be capable of producing memory B cells or maternal antibodies in fetus [38, 39].

Intrigued by these findings, we attempted to assess the role of a hematopoietic component in UCB in vertical transmission and its specificity to DENV protein. Hence, we investigated the feasibility of targeting primitive hematopoietic cells CD34 and CD133 and their association with DENV NS1 protein. CD34 and CD133 are cell surface glycoproteins found specifically in undifferentiated cells with approximately 0.02–1.43%, and 0.1–0.4% mononuclear cells of UCB are CD34+ and CD133+, respectively [40, 41]. The purpose of this study was to assess the potency of CD34+ CD133+ HSCs in UCB to be infected by DENV and the effects of DENV infection to the expression of hematopoietic GATA factors to demonstrate the functional abnormalities during hematopoietic differentiation in DENV-infected UCB. GATAs are essential regulators in the development of hematopoietic cell lineage and the molecular pathogenesis of diseases [42]. A series of publications, mainly registered case reports, highlighting the clinical history of maternal dengue during pregnancy with no apparent explanation accounting for the significant carrier of DENV from mother to fetus and cellular level mechanism of vertical transmission [43, 44, 45]. We therefore hypothesized that stem cells in UCB might serve as an amplification reservoir for DENV during vertical transmission from the placenta to the neonate. We have therefore established an in vitro experimental model to document that DENV indeed efficiently infects human umbilical cord blood cells (HUCB) and serves as a potential carrier of DENV.

2. Methods

2.1. Human umbilical cord blood collection and preparation of the UCB for DENV infection

Pregnant women with written informed consent participated in this study, following the protocol (IRB, A-ER-103-184) approved by the Institutional Review Board of National Cheng Kung University Hospital. Total UCB cells were counted after initial treatment to remove red blood cells by RBC lysis buffer (Qiagen Inc, USA). 2 × 10⁷ cells/ml were suspended in RPMI medium (HyClone, USA) supplemented with 10% FBS (Gibco, Ireland) and 1 × 10⁷ cells/ml were infected with DENV-2 (16881 strain) with 1 MOI (Multiplicity of infection). In parallel, a control tube of uninfected UCB cells (1 × 10⁷ cells/ml) was prepared. Supernatants and cells were harvested at specific time points of post-infection (PI) days (D0, D1, D2, D3, D5, D7, D10, and D14) to quantify the viral load from DENV-infected UCB supernatant using plaque assay. The detail descriptions of the protocols were provided in Supplementary Data.

2.2. Immunophenotyping and multicolor flow cytometry analysis (MFCM)

The cells harvested at indicated time points were subjected to MFCM by staining with fluorescence-conjugated antibodies for phenotypic analysis of hematopoietic stem and progenitor cells (HSPC) in infected and uninfected cells. All staining was performed in PBS containing 1% BSA. Mouse anti-human surface marker antibodies, specific for the HSC, sub-populations of myeloid cell lineage and GATA TFs with their respective isotype controls (BD Biosciences, Research and Design), listed in the Supplementary Table S6A-B. The cells were acquired using LSR Fortessa (BD Bioscience) for MFCM analysis. To analyze and confirm the association of NS1 expression with CD133 or CD34 cells in DENV-infected UCBs, IFA was performed from D1 to D14. Fluorescent images were captured in an Inverted Confocal Microscope FV-1000 (Olympus). The detail methods were described in Supplementary Data.

2.3. Sorting of CD133+ and CD34+ cells and co-culture with Vero cells

CD34 and CD34 markers of HSCs were isolated from UCB cells by magnetic cell sorting (Miltenyi Biotec) a cell sorter (MoFlo XDP cell sorter, Beckman Coulter). A total of 1 × 10⁶ cord blood cells was processed to isolate pure populations of the positive and negative fractions of CD34 and CD133 cells, respectively. The sorted CD34+ and CD133+ cells were then infected with DENV at MOI = 1 and cultured in 10% RPMI to monitor the virus production at the indicated time points from D0 to D14. In addition, CD34+ and CD133+ cells with negligible virus production in supernatants were subsequently co-cultured with Vero cells to recover the infectious virus (Figure 7B). 1 × 10⁵ Vero cells per well were seeded in 24-well microplates one day before the harvested time point to allow the formation of a monolayer. CD34+ and CD34+ cells reconstituted with 500 μl of 2% DMEM were co-incubated with Vero cells (5% CO2, 3 7°C) for 7 days to observe cytopathic changes. Two hundred microliter of the supernatant was collected daily from day 2 to day 7 post co-cultures, and each well was replenished with an equal amount of 2% PBS DMEM. The co-cultured supernatant was subjected to plaque assay.

2.4. Temporal heterogeneity of CD133+ and CD34+ using t-SNE

To observe the spatial and temporal changes of stem cell populations, double-positive NS1, CD34+, and NS1 CD133+ cells from each of the 7 donors were clustered together to generate a single concatenate file using coloring parameters from Flow Jo version 10. This technique enabled us to create a t-SNE distribution map of different time points during DENV infection in UCBs. It was ensured that debris was excluded during the gating of the live cells based on FSC/SSC plot. The density of different levels of CD34+ NS1+ and CD133+ NS1+ expressed over time were color-coded. The parameters utilized to generate the t-SNE map were as
follows: down sample = 50,000 cell events, iteration = 1000 and perplexity = 100. Next, we systematically assess the expression level of CD133<sup>+</sup> on CD34<sup>−</sup>NS1<sup>+</sup> and CD34<sup>+</sup> on CD133<sup>−</sup>NS1<sup>−</sup> cell density plot using t-SNE analysis. The detail descriptions of the protocol were provided in Supplementary Data.

3. Results

3.1. Human UCBs were infectable by DENV, resulting in an increase of HSC population and a decrease in progenitor cells

We first investigated the permissivity of UCB to DENV by determining whether DENV amplification took place in UCB. The average viral titer of DENV-infected UCBs supernatant demonstrated that UCB could be efficiently infected by the DENV with a peak titer on day 7 (Figure 1A), although a variation in the individual donors was observed, denoted in Supplementary Figure S1 and Supplementary Table S1. We then compared the distribution of the surface markers-defined phenotypes of HSPC from the cells collected from DENV-infected UCB. Based on the established markers of HSPC (Figure 1B) [46], each population was stained with respective antibodies indicated in Supplementary Table S6A for myeloid lineage and HSC. Gating strategy of HSPC subsets of CMP, EMP and MEP with NS1 plot was described in Supplementary section (Supplementary Figure S2). The data revealed a fold decrease of HSC on D7 PI in comparison to D5 and D10 in DENV-infected UCB cells (Figure 1C). When compared to respective lineage progenitors (HSPC), HSC was markedly high, and other myeloid lineages were inhibited significantly (unpaired t-test was applied to compare each population, \( P < .001^{***} \)). We found a significant correlation of HSC with average viral load (\( P = .046^{*} \)). The overall population of HSCs was increased in UCB during early phases (D5-D7). Similarly, GATA-2 bearing HSC was also slightly increased on D7 (Figure 2A and B), corresponding with the height of virus production at D5 and D7 (Figure 1A). In contrast, GATA-1 and GATA-2 bearing megakaryocytic lineages EMP and MEP were decreased in comparison to HSC, indicating reduced differentiation of HSC to MK. GATA -1 and GATA-2 expressing EMP lineages were strictly inhibited in early phases from D0-D7 and became predominantly high from D10. GATA-1 bearing MEP was suppressed through the time course (D0-D10), while a slight increase of GATA-2 expressing MEP was seen on D7. Similarly, GATA-3 expressing in HSCs found to increase over time (D0-D1 and D5-D10), a high degree of GATA-3 was expressed in EMP and preventing downstream differentiation into definite lineage (Figure 2C). The three TFs also showed some proneness towards CMP during initial phases of infection, indicating an upward trend of monocytes while this lineage combated the virus, which later subsided after D3. Overall, our results suggested that the population of HSC that expressed GATA TFs increased after DENV infection, while there was an inhibition of EMP along with other progenitor cells, MEP and CMP expressing TFs in total cells of UCB (Supplementary Figure S2.1 B-D). Average values of actual number of gated cells expressing GATA-1, GATA-2 and GATA-3 obtained after gating only live cells were presented in Supplementary Table S2. It became increasingly apparent that DENV promoted HSC proliferation while inhibiting the cell population within myeloid lineage. Thus, we next

3.2. Functions of transcription factors GATA-1, GATA-2, and GATA-3 in DENV-infected UCBs

To explore the cause of increased expression of HSC and altered hematopoiesis in DENV-infected UCB, we investigated the potential role of GATA TFs and compared the variation in specific cell populations. To show the differential expression of lineage progenitors, we depicted the relative percentage of cell populations from each subpopulation in the form of Heat Map. Based on the low and high fold change of phenotypic expression from the normalized values, GATA-1 expression in HSC was increased in DENV-infected UCBs during early phases (D5-D7). Similarly, GATA-2 being HSC was also slightly increased on D7 (Figure 2A and B), an increasing form of Heat Map. Based on the low and high fold change of phenotypic expression from the normalized values, GATA-1 expression in HSC was increased in DENV-infected UCBs during early phases (D5-D7). Similarly, GATA-2 bearing HSC was also slightly increased on D7 (Figure 2A and B), while a slight increase of GATA-2 expressing EMP was seen on D7. Similarly, GATA-3 expressing in HSCs found to increase over time (D0-D1 and D5-D10), a high degree of GATA-3 was expressed in EMP and preventing downstream differentiation into definite lineage (Figure 2C). The three TFs also showed some proneness towards CMP during initial phases of infection, indicating an upward trend of monocytes while this lineage combated the virus, which later subsided after D3. Overall, our results suggested that the population of HSC that expressed GATA TFs increased after DENV infection, while there was an inhibition of EMP along with other progenitor cells, MEP and CMP expressing TFs in total cells of UCB (Supplementary Figure S2.1 B-D). Average values of actual number of gated cells expressing GATA-1, GATA-2 and GATA-3 obtained after gating only live cells were presented in Supplementary Table S2. It became increasingly apparent that DENV promoted HSC proliferation while inhibiting the cell population within myeloid lineage. Thus, we next
investigated the capacity of the infected UCBs to differentiate into specific lineages by performing a colony-forming assay. There was no visible trend between uninfected and challenged groups. A decreasing trend in myeloid lineages CFU-GM and CFU-GEMM after DENV infection was observed, though the difference was not statistically significant (Supplementary Figure S2.2). However, the results from colony-forming assay suggested that the differentiation of myeloid progenitor cells was obviously affected during DENV infection. The detail descriptions of the protocol for colony-forming assay were provided in Supplementary Data.

3.3. DENV infection upregulated the expression of CD34<sup>+</sup> and CD133<sup>+</sup> HSCs

Based on the functionality of GATA TFs on distinct sub-populations, the expression of transcriptional GATA factors was found to be coordinated with the changes in HSPCs of infected UCB cells, resulting in an overall increment in HSC population. We then focused on the CD133<sup>+</sup> and/or CD34<sup>+</sup> HSCs surface markers in DENV-infected UCBs by MFCM. The strategy for quadrant gating of CD133<sup>+</sup> and/or CD34<sup>+</sup> cells is shown in Figure 3A. Results indicated that there was a gradual increase in
CD133⁺CD34⁺ subset as well as single positive CD133⁺ and CD34⁺ populations. Furthermore, a significant positive correlation was found between the absolute number of CD133⁺ and CD133⁻ cells (Figure 3B). Actual number of cells is provided in Supplementary Table S3 A-C.

3.4. Coordinated changes of CD133⁺/⁻ CD34⁺/⁻/NS1⁺ cells in DENV-infected cord blood cells

Next, we extended our analysis to evaluate the time-related variation in subsets levels of CD133⁺/⁻ CD34⁺/⁻/NS1⁺ cells in DENV-infected UCB at a different stage of infection to show the kinetic of cell content (Figure 4A). The fold changes in the gating percentage of CD34⁺ NS1⁺, and CD133⁺ demonstrated that CD34⁺ NS1⁺ and CD133⁺ NS1⁺ increased on D5 and decreased on D7, followed by an upward surge on D10 PI. In contrast, CD133⁺ CD34⁺ NS1⁺ cells had an intermittent increase on D7, a major drop on D10, and another increase on D14 PI (Figure 4B). Actual number of cells CD133⁺ NS₁⁺, CD34⁺ NS₁⁺ and CD133⁺ CD34⁺ NS₁⁺ cell population from DENV infected UCB obtained after gating the cells was provided in Supplementary Table S4 A-C. Representative example of flow analysis of CD133 and CD34 with NS1 expression was presented in Figure 4A and Supplementary Figure S3.1. To show the kinetic and modulation of NS1⁺ on CD133⁺ CD34⁺ double-positive cells in DENV-infected UCB, gated frequencies of NS1⁺ on CD133⁺ CD34⁺ cells from one donor was presented in Supplementary Figure S3.2A. Frequencies of gated NS1⁺ were calculated as described in Supplementary Figure S3.2B. Above all, the results showed that NS1⁺ could have an impact on CD133⁺ and/or CD34⁺ populations; even though the number of CD34⁺ CD133⁺ was relatively increased, indicating that NS1 may modulate the function of stem cells.

3.5. Characterization of NS1 with CD133⁺ and CD34⁺ cells in DENV-infected UCBs using immunofluorescence assay

The fluorescence assay demonstrated that NS1 was expressed in CD34⁺ cells which reached the maximum after D10 PI (Figure 5A and B). In addition, NS1 was also expressed in CD133⁺ cells, and the peak of NS1 expression was on D5 PI (Figure 5D and E). Mock controls for CD34⁺ and CD133⁺ cells were performed in parallel (Figure 5 C and F). As expected, CD34⁺ NS₁⁺ IFA data coincided with the results observed in MFCM analysis. On the contrary, there was a subtle discrepancy in the data of NS1⁺ CD133⁺ on D10. This form of CD133 antibody was probably not properly detected in all the fields by the fluorescent secondary antibody on D10 in immunostaining, and, therefore, the total number of infected cells per field was less comparable to D5 and diverged from MFCM data (Figure 4B). We rationalized that due to excessive proliferation of CD133 on D10 as shown by the following t-SNE analysis (Figure 6C); DENV might have affected the binding of antibodies to infected stem cells presumably by reducing the binding affinity to surface proteins.

3.6. Temporal heterogeneity of CD133, CD34, and NS1 using t-SNE

To better understand the variation in expression of CD34⁺ or CD133⁺ cells with NS1, we used a dimensionality reduction technique t-SNE (t-Distributed Stochastic Neighbor Embedding) on a dataset (N = 7) to...
visualize the distribution of CD133 and CD34, as well as their co-expression with NS1 (Figure 6A). This technique enabled us to create a t-SNE map the distribution levels of CD34\(^+\)NS1\(^+\) and CD133\(^+\)NS1\(^+\) among the different time points during DENV infection in UCBs (Figure 6B and C) (The peak intensities of CD34\(^+\)NS1\(^+\) and CD133\(^+\)NS1\(^+\) were higher on D10 and D14, corresponding to the fold increased gating kinetics from MFCM (Figure 4B). Notably, the expressions of CD34\(^+\)NS1\(^+\) and CD133\(^+\)NS1\(^+\) cells were decreased on D7. The decrease of double-positive subsets could be a consequence of increasing triple-positive CD133\(^+\)CD34\(^+\)NS1\(^+\) population (Supplementary Figure S4). The t-SNE maps demonstrated that CD133\(^+\)CD34\(^+\)NS1\(^+\) cells were susceptible to becoming triple-positive on D7 when the viral titer was high but then decreased at D10 PI (Supplementary Figure S4 A and B). Further, to explore the association of NS1 with different lineages of stem cells, mapping of functionally defined groups of sub-populations confirmed elevated expression of HSC (Supplementary Figure S4.1). Differences in levels of EMP, CMP, and MEP were also evident with notably higher HSC expression.

3.7. Confirmation of the infectivity of virus in specific sorted CD133\(^+\) and CD34\(^+\) cells as well as the recovery of infectious virus from these cells

To verify the infectivity of DENV in CD133\(^+\) and CD34\(^+\) cells, the cells were respectively sorted out from UCBs. More than 1 \(\times\) 10\(^6\) cells were obtained after sorting from 1 \(\times\) 10\(^8\) total UCB. They were subjected to DENV infection, and the supernatants were collected for plaque assay at indicated time points. The average loads of infectious virus in supernatants of sorted CD34\(^+\) or CD133\(^+\) cells are shown in Figure 7A. The viral titer in sorted CD34\(^+\) cells from different UCB donors varied as clearly shown in Table 1. The sorted CD34\(^+\) cells produced ample virus up to D14 with 8500 pfu/ml at D1 in donor 1, whereas in donors 2, 4 and 5, there was no detectable virus in the supernatants of sorted CD34\(^+\) cells. In contrast, viral loads in supernatants of sorted CD133\(^+\) cells were more notable in most of the donors except for donor 2 (Table 1). Supernatants obtained from sorted CD133\(^+\) cells from 5 donors (Donor 2-Donor 6) were subjected to co-culture with Vero cells (Figure 7B). The titer of virus recovered through co-culture is shown in Table 2. We observed that Donor 3 had a detectable yield of the virus in the supernatants of infected CD133\(^+\) cells at D5 with 100 pfu/ml, but no detectable viral outputs in the supernatants of infected CD133\(^+\) cells were observed from D7 to D14 (Table 1). Unexpectedly, the same CD133\(^+\) cells from D7 were able to produce a large quantity of virus with a titer of 1.7 \(\times\) 10\(^5\) pfu/ml after 5 days of co-culture (Table 2). Similarly, donor 3 had no virus yield from
D10 in supernatants of DENV-infected CD34⁺ cells. Upon co-culturing the CD34⁺ cells, the supernatants contained a marginal production of virus with about 100 pfu/ml up to day 7 (Table 1, Table 2). These results indicated that the CD133⁺ and CD34⁺ cells were not only infectable by DENV but could also serve as the reservoir for the virus (Figure 7C). The infectivity of DENV in the sorted CD34⁺ and CD133⁺ cells were further corroborated by IFA staining, in which both cells were shown to express NS1 protein. IFA staining also showed that CD133⁺ cells had a higher number of NS1 co-expressing cells as compared to CD34⁺ cells (Figure 7D). The virus recovery from CD133⁺ cells was more notable in co-culture with Vero cells at day 5 and sustained up to day 7 as compared to CD34⁺, which increased on day 7 in donor 3. This reveals that CD133⁺ cells are more spontaneous in virus reactivation and more susceptible to active infection, whereas CD34⁺ cells are not very significant in reactivation and predominantly latent.

4. Discussion

In this study, we demonstrated that human UCBs were highly permissive to DENV infection. Studies have described the presence of
Figure 7. Confirmation of the infectivity of virus in specific sorted CD133+ and CD34+ cells as well as the recovery of infectious virus from these cells (A) Schematic representation of sorting and enrichment of CD133+ and CD34+ stem cells and viral load from the supernatant (n = 6). (B) Schematic presentation of the co-culture system. Infected CD133+ and CD34+ cells obtained from each time point with no infectious virus in the supernatant were co-cultured with Vero cells. (C) The replication curve of the recovered virus from infected CD133+ and CD34+ cells (n = 5). (D) Immunofluorescence staining of CD133+ and CD34+ with NS1+ obtained from co-culture.

Table 1. Viral titers from sorted CD133+ and CD34+ cells after DENV infection.

| Days P.I. | Donor 1 CD34+ | CD133+ | Donor 2 CD34+ | CD133+ | Donor 3 CD34+ | CD133+ | Donor 4 CD34+ | CD133+ | Donor 5 CD34+ | CD133+ | Donor 6 CD34+ | CD133+ |
|----------|----------------|--------|----------------|--------|----------------|--------|----------------|--------|----------------|--------|----------------|--------|
| 0        | 50             | 0      | 0              | 0      | 0              | 0      | 0              | 0      | 0              | 0      | 0              | 0      |
| 1        | 8500           | 1      | 0              | 0      | 250            | 0      | 25             | 0      | 75             | 0      | 1512.5         | 0      |
| 2        | 250            | 100    | 0              | 0      | 2500           | 350    | 0              | 175    | 0              | 1800   | 25             | 13     |
| 3        | 213 *          | 0      | 0              | 1475   | 150            | 0      | 1215           | 0      | 38             | 0      | 38             | 0      |
| 5        | 0              | 0      | 0              | 150    | 100            | 0      | 375            | 0      | 163            | 0      | 63             | 0      |
| 7        | 0              | 0      | 275            | 0      | 0              | 0      | 50             | 0      | 625            | 0      | 50             | 0      |
| 10       | 0              | 0      | 0              | 0      | 0              | 0      | 0              | 0      | 0              | 0      | 225            | 0      |
| 14       | 1425           | 0      | 0              | 0      | 0              | 0      | 0              | 0      | 0              | 0      | 0              | 0      |

*Supernatants obtained from sorted CD133+ cells from donor 1 were contaminated after Day 2.

Table 2. Viral load after co-culture.

| Co-c. d Co-c. d |
|-----------------|
| 14 10 7 10 14 14 |
| 2 0 0 12.5 200 12.5 0 0 0 0 0 25 |
| 5 0 0 25 175000 0 0 0 0 0 0 0 |
| 7 0 0 100 250 0 0 0 0 0 0 0 |

*Co-c. d: Day of Co-culture.
**D.P Co-c: Days Post Co-culture.
preinfectional antibodies and phenomena of enhancement of DENV antibodies in cord blood [47, 48]. Our observations, although from a small sample size, revealed that HUCB serum from each participant was serologically negative for DENV IgG and IgM, which coincides with a previous report suggesting that the prevalence of DENV antibodies in the general population in Taiwan is low (Supplementary Table S5) [49]. Indication of IgM and IgG antibodies in cord blood serum of neonates is suggestive of transplacental transfer of DENV and transfer of maternal IgG antibodies [50]. In recent years, it has been explored that hematopoietic cell candidates express FcRn receptor to recycle internalized IgG and maintain IgG level [51, 52]. Studies of infants with dengue in which cord blood serum is used to define the entity of the disease enhancement [47] will, therefore, not discern the relative infectivity of invading hematopoietic cells as well as antibodies-producing cells from the mother. To better comprehend cell-associated virus infectivity, we emphasized the potential importance of stem cells in UCB to demonstrate a possible route of perinatal transmission. Previously published reports have shown the impact of congenital infection on the markers of hematopoietic progenitor cell potency [53]. Besides, the association of DENV antigen with trophoblast, stromal cells and decidua in placental tissue has been reported [54]. However, no reports are suggesting that HSCs in HUCB are also capable of getting infected by DENV, which could also play a role in vertical transmission. In line with this notion, we hypothesized that hematopoietic stem cells in UCB are the first potential target to be exploited by the virus, leading to congenital infection. We evaluated the myeloid lineage as the target for DENV in UCB cells. Our results revealed that HSCs increased after DENV infection in in vitro analysis of UCB.

In earlier reports, viral hematodepressive disease without serological identity has been diagnosed in Thai children [55]. Infants with primary dengue had significantly lower platelet nadirs and greater hematocrit-concentration [20]. This raises the distinct possibility that certain aspects of hematopoietic response to virus infection remain obscure. As reported, GATAs are the transcription factors that operate sequentially in the activation and repression of genes in the development of blood cells and orchestrate cell differentiation and proliferation [56, 57]. The phenotypic and functional characteristics of GATA TFs investigated in our study suggested that hematopoietic GATA factors could be intertwined with the differentiation of HSC in DENV-infected UCB, as documented in a prior study [58]. DENV-associated thrombocytopenia caused the inhibition of HSC differentiation to MK development in BM to reduce the production of platelets. Combining our results, we found that there was an altered expression of these TFs that changed the balance of transcription factors, which may explain the disordered hematopoiesis due to DENV infection (SF2). This implies that in early infancy, the maturation arrest of HSC caused by DENV infection in UCB leads to inhibition of the myeloid lineage and predisposes HSCs to interact with DENV, thereby potentially causing damage to MK production. The fact that protection provided by maternal dengue antibodies lasts 6 months or less in infants, consequently leaving them susceptible to dengue virus infection [47], and causing increased vascular permeability compared to adults, raises the question of whether other sensitized cells with specific virus receptors may mediate infection from mother to the fetus.

There is growing evidence that hyaluronan receptor CD44 plays a substantial role in the increased vascular permeability and decreased platelet count associated with severe dengue infection [59, 60]. Considering the evidence, that CD44 as a provocative mediator in severe dengue infection [55, 61], our in vitro study cannot fully explain the speculation for UCB challenging to be infected [71]. The influence of maternal age on UCB HSC concentration as well, reinforces the speculation for UCB to potentially confer vertical transmission and reactivation of the virus. Lastly and most importantly, one of the donors in our study whose serological test scored negative anti-DENV IgG and IgM had dengue fever and delivered twins (Mother 8). One infant was normal and the other had dengue infection. In the plaque assay using the infectious culture supernatant of cord blood, twin A with DENV infection produced a high viral load in sorted CD34+ and CD133+ cells, in contrast to twin B with no virus production. From this result, we speculated that stem cells in twins could have other unknown factors contributing to the susceptibility of CD34+ and CD133+ to DENV infection. Literature suggest that there is an individual variation to DENV infection among twins, which is consistent with the previous report [70]. The influence of maternal age on UCB HSC concentration as well, reinforces the speculation for UC challenges to be infected [71]. However, in our in vitro study cannot fully attribute a substantial role to HSCs in maternal-fetal transmission. Our approach needs to be further explained by animal modeling or in vivo studies.
Declarations

Author contribution statement

Guey Chuen Perng: Conceived and designed the experiments; Wrote the paper.

Amrita Vats: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Tzu-Chuan Ho, Irwin Puc, Chiung-Hsin Chang: Reagent, materials, analysis tools or data; Yi-Ju Chen: Performed the experiments.

Yu-Wen Chien: Analyzed and interpreted the data.

Funding statement

This work was supported by Taiwan Ministry of Science and Technology (MOST-106-2321-B-006-012; MOST 107-2314-B-006-MY3 and MOST 103-2320-B-006-030-MY3).

Data availability statement

Data included in article-supplementary material/referenced in article.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.helyon.2021.e06785.

References

[1] World Health Organization, Global Strategy for Dengue Prevention and Control 2012-2020, World Health Organization, Geneva, 2012.
[2] D.S. Burke, D.S, A. Nisalak, D.E. Johnson, R.M. Scott, et al., A prospective study of dengue infections in Bangkok, Am. J. Trop. Med. Hyg. 38 (1) (1988) 172–180.
[3] T. Back, A. Lundkvist, Dengue viruses - an overview, Infect. Ecol. Epidemiol. 2 (2013).
[4] J.M. Heilmann, J. DeWolff, Beats,Beards, B.M. Jensen, et al., Dengue fever: a Wikipedia clinical review, Open Med. 8 (4) (2014) e105–e115.
[5] R.K. Gupta, G. Gupta, V.K. Chorasiya, P. Bag, R. Shandil, V. Bhatia, M. Wadhawan, Deaths linked to dengue fever: a prospective study of dengue virus transmission by blood stem cell donor after travel to Sri Lanka, Germany, Emerg. Infect. Dis. 20 (8) (2014) 1366–1369, 2014.
[6] K. AS, Transmission of Maternal Memory, Clinical Research Division. Science 395 (2020), S632.
[7] Kariyawasam, S. and H. Senanayake. Dengue infections during pregnancy: case report and literature review, J. Med. Assoc. Thai. 86 (Suppl 3) (2013) 1133–1415.
[8] K. AS, Transmission of Maternal Memory, Clinical Research Division. Science 395 (2020), S632.
[9] A. Hau, T.C.H. Ho, M.L. Lai, et al., Identification and characterization of permissive cells to dengue virus infection in human hematopoietic stem and progenitor cells, Transfusion 59 (9) (2019) 2938–2951.
[10] N.A. Mohamed Ismail, S.S. Azura, I.R. Jama, A.K. Salie, et al., Seropositivity of dengue infection during pregnancy and transplacental antibody transfer in Thai mothers, J. Infect. 51 (4) (2005) 287–295.
[11] K. Perrett, P. Chanthavanich, K. Pengsa, K. Limkittikul, K. Hutajaroen, Bunn, et al., Placental transfer of dengue virus (DENV)-Specific antibodies and kinetics of DENV infection-enhancing activity in Brazilian infants, J. Infect. Dis. 214 (2) (2016) 265–272.
[12] L. Mathiesen, L.K. Nielsen, J.T. Andersen, A. Greys, et al., Maternofoetal transplacental transport of recombinant IgG antibodies lacking effector functions, Blood 122 (7) (2013) 1174–1181.
[13] G.C. Perng, Role of bone marrow in pathogenesis of viral infections, J. Bone Marrow Regen Res 1 (2012).
[14] A. Rojas, A.C. Gourinat, C. Cazorla, C. Joubert, D.M. Rouzeyrol, E. Descloux, et al., A prospective study of dengue virus transmission by blood stem cell donor after travel to Sri Lanka; Dengue virus transmission by blood stem cell donor after travel to Sri Lanka; Emerging infectious diseases, Emerg. Infect. Dis. 20 (8) (2013) 1366–1369, 2014.
[15] A. Gupta, S. Kuamri, A. Singhal, A. Bahl, Neonatal thrombocytopenia and platelet dysfunction and enhancement activity in Brazilian infants, J. Infect. Dis. 214 (2) (2016) 265–272.
[16] V. Watanaveeradej, T.P. Endy, R. Samakoses, S. Kerdpanich, S. Simanathith, et al., Transplacentally transferred maternal-infant antibodies to dengue virus, Am. J. Trop. Med. Hyg. 69 (2) (2003) 123–128.
[17] S.C. Klöks, S. Nimmanitya, A. Nisalak, D.S. Burke, et al., Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants, Am. J. Trop. Med. Hyg. 38 (2) (1988) 411–419.
[18] N.A. Mohamed Ismail, S.S. Azura, I.R. Jama, A.K. Salie, et al., Seropositivity of dengue antibodies during pregnancy, ScientificWorldJournal (2014), 436975.
[19] C. Basurko, S. Matheus, M. Restrepo, H. Hilderal, S. Everhard, M. Azevedo, et al., Recent advances in understanding dengue, F1000Res (2019) 8.
[20] C.P. Simmons, T.N.B. Chau, T.T. Thuy, N.M. Tuan, et al., Maternal antibody and viral factors in the pathogenesis of dengue virus in infants, J. Infect. Dis. 196 (3) (2007) 416–424.
[21] C.R. Machado, E.S. Machado, R.D. Rohloff, M. Azevedo, D.P. Campos, C. Basurko, S. Matheus, H. Hilderal, S. Everhard, M. Azevedo, et al., Recent advances in understanding dengue, F1000Res (2019) 8.
